Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 21829-25-4 | Product Number: N0528
Nifedipine
×
![]()
×
Purity: >98.0%(E)(HPLC)
Synonyms:
- 1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic Acid Dimethyl Ester
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 10G |
$71.00
|
3 | 2 | ≥40 |
|
| 25G |
$129.00
|
3 | 1 | 34 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | N0528 |
| Purity / Analysis Method | >98.0%(E)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__7H__1__8N__2O__6 = 346.34 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Condition to Avoid | Light Sensitive |
| CAS RN | 21829-25-4 |
| Reaxys Registry Number | 497773 |
| PubChem Substance ID | 87573853 |
| SDBS (AIST Spectral DB) | 9750 |
| Merck Index (14) | 6528 |
| MDL Number | MFCD00057326 |
Specifications
| Appearance | Light yellow to Yellow to Orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(UV-vis method) | min. 98.0 % |
| Melting point | 172.0 to 175.0 °C |
| Solubility in Acetone | almost transparency |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 174 °C |
| Solubility (soluble in) | Chloroform, Acetone |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
Related Laws:
| RTECS# | US7975000 |
Transport Information:
| HS Number | 2933.39.9200 |
Application
Type IV secretion system (T4SS) research
Reference
- Chemical Genetics Reveals Bacterial and Host Cell Functions Critical for Type IV Effector Translocation by Legionella pneumophila
Application
Nifedipine: A Short-Acting Dihydropyridine Calcium Antagonist
Nifedipine is a short-acting dihydropyridine calcium antagonist. It selectively inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle without altering serum calcium concentrations, and induces a relaxation of the muscle. Because of the dilation of resistance vessels, blood pressure falls. Nifedipine is almost completely metabolized by cytochrome P450 3A4 (CYP3A4) in the liver. Nifedipine is a poorly water soluble agent and rapidly metabolized resulting in decreased bioavailability, and then the short-acting can provide increased the risk of stroke et al. Therefore, nifedipine slow-release formulations have been developed. (The product is for research purpose only.)
References
- Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischemic heart disease, hypertension and related cardiovascular disorders
- Comparative pharmacology of calcium antagonists: nifedipine, verapamil [V0118] and diltiazem [D3662] (a review)
- Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine
- In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: Role of CYP3A4 and CYP3A5
- Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris (a review)
- Analysis of nifedipine and its pyridine metabolite dehydronifedipine in blood and plasma: review and improved high-performance liquid chromatographic methodology
Application
Photobase Generator
References
- S. Song, S. Yokoyama, S. Takahara, T. Yamaoka, Polym. Adv. Technol. 1998, 9, 326.
- S. Song, S. Takahara, T. Yamaoka, J. Photopolym. Sci. Technol. 1998, 11, 171.
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.